Bioquark, Revita Life Sciences partner on regenerative medicine for spinal cord injuries: 4 points

Written by Megan Wood | February 05, 2016 | Print  |

Bioquark, a Philadelphia-based biologic-based product developer, and Revita Life Sciences, an India-based biotechnology stem cell company, are collaborating to develop regenerative medicine for spinal cord injuries.

Here are four points:

 

1. The two companies plan to combine their cellular and biologic expertise to create a transformational regenerative medicine solution.

 

2. The initiative will work on complex regenerative solutions by researching ways to reprogram cells in damaged tissues.

 

3. The medical costs associated with spinal cord injury exceed $20 billion every year in the United States.

 

4. "The ability to merge cellular and biologic approaches represents the next evolutionary step in achieving complete regeneration and full functionally in this devastating disease," said Dr. Himanshu Bansal, managing director, Revita Life Sciences.

 

More articles on spine:
Orthobiologics in spinal fusion: 5 key notes on outcomes for Cerapedics' i-FACTOR
Dorsal lumbar fusions: 5 things to know about how BMP affects cost
Drs. Juan Ronderos, Victor Perry & more: 8 spine, neurosurgeons in the headlines this week

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months